Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Operating Expenses: 2009-2025

Historic Operating Expenses for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $411.0 million.

  • UNITED THERAPEUTICS's Operating Expenses rose 1.28% to $411.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 10.71%. This contributed to the annual value of $1.5 billion for FY2024, which is 31.31% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Operating Expenses stood at $411.0 million, which was down 5.32% from $434.1 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Operating Expenses ranged from a high of $443.9 million in Q1 2021 and a low of $173.9 million during Q1 2022.
  • Over the past 3 years, UNITED THERAPEUTICS's median Operating Expenses value was $378.2 million (recorded in 2024), while the average stood at $354.5 million.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Operating Expenses soared by 134.12% in 2021 and then plummeted by 60.82% in 2022.
  • UNITED THERAPEUTICS's Operating Expenses (Quarterly) stood at $245.4 million in 2021, then grew by 28.73% to $315.9 million in 2022, then increased by 12.25% to $354.6 million in 2023, then rose by 6.66% to $378.2 million in 2024, then rose by 1.28% to $411.0 million in 2025.
  • Its Operating Expenses was $411.0 million in Q3 2025, compared to $434.1 million in Q2 2025 and $411.6 million in Q1 2025.